Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
ATOS•ATOS•ATOS•ATOS•Atossa Therapeutics reported a third-quarter net loss of $5.64 million as operating expenses fell to $5.9 million, citing lower clinical trial and legal costs.
Atossa Therapeutics said its third-quarter net loss narrowed from the year-earlier period. Operating expenses were $5.9 million, with the company citing lower clinical trial expenses after enrollment was completed in (Z)-endoxifen studies and lower legal fees following the resolution of patent litigation.
The company expects FDA investigational new drug clearance for (Z)-endoxifen in MAS and DMD by early 2027 and topline data from its Phase 2 EVANGELINE study in the second quarter of 2027. Select I-SPY2 study data are scheduled for presentation at SABCS in December 2026. Atossa also announced contingent value rights tied to potential future monetization of a priority review voucher.
